A. Riluzole was approved on the basis of data showing prolonged survival and slower decline in function B. Riluzole can cause increased liver function tests so monitoring should be performed C. The length of riluzole therapy is determined according to symptom improvement D. The length of riluzole therapy is determined according to the presence of side effects E. Unsure

A. His symptom onset was greater than 6 months ago, so he is unlikely to benefit from edaravone B. His ALSFRS-R score is not low enough to expect benefit from edaravone C. His family and genetic histories must confirm he has sporadic ALS to expect benefit from edaravone D. His FVC may limit any benefit, but edaravone is still indicated according to United States Food and Drug Administration (FDA) labeling E. Unsure

A. Edaravone does not require pre-medications and can be administered by home infusion B. Edaravone can be administered on an alternative “vacation” dosing schedule according to its labeling C. A daily dose of edaravone is administered over 60 minutes D. Edaravone does not require chemotherapy precautions, so it does not need to be infused at an infusion center E. Unsure

A. ALS typically affects motor neurons and cognitive impairment is not usually present B. Newer data suggest cognitive impairment affects up to 50% of ALS patients C. Edaravone and riluzole are not indicated in patients with ALS and FTLD D. Edaravone would be the preferred treatment for patients with FTLD since it is administered orally E. Unsure